Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Researchers analyze how genome influences human health

Two recent studies by Dartmouth researchers use individual genetic data to reveal the powers and limits of our current understanding of how the genome influences human health and what genes can reveal about the ancestry of the people of New Hampshire.

15 Sep 2009

CPEX Pharmaceuticals to discuss the clinical aspects of nasal insulin therapy

CPEX Pharmaceuticals, Inc. (“CPEX”) today announced that it will participate in the Ninth Annual Diabetes Technology Meeting to be held November 5–7, 2009, at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to present an oral presentation titled “The Technology and Clinical Aspects of Nasal Insulin Therapy” at 9:30 a.m. PST on Saturday, November 7, 2009.

15 Sep 2009

Lexicon initiates Phase 2 clinical trial of LX4211 in patients with type 2 diabetes mellitus

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus.

15 Sep 2009

Genova gains access to Big Pharma's distribution channels

GENova Biotherapeutics Inc. ("GENova"), a cancer drug acquisition and development company, is pleased to announce it has gained access to distribution channels for its promising drug targets through a recently-signed deal with Bridge BioResearch Plc. ("Bridge BioResearch").

15 Sep 2009

GENova Biotherapeutics and Bridge Bioresearch sign collaboration agreement

GENova Biotherapeutics Inc. ("GENova") today announced it has signed a collaboration agreement with Bridge Bioresearch Plc. ("Bridge Bioresearch"), an international drug development and discovery company that focuses on metabolic disorders.

15 Sep 2009

Campaign for prevention and control of head lice

The National Association of School Nurses (NASN) announced today the kickoff of S.C.R.A.T.C.H. (School and Community Resources to Avoid and Take Control of Head Lice), a campaign to educate school nurses, students, parents and the general public about the prevention and control of head lice.

14 Sep 2009

Children with larger waists are more at risk of developing cardiovascular disease later in life

Children with more fat around their midsections could be at a higher risk of developing cardiovascular disease later in life, researchers say.

11 Sep 2009

HHS, Ad Council and Warner Bros unite to address childhood obesity

The U.S. Department of Health and Human Services (HHS) and the Ad Council today launched a new series of public service advertisements (PSAs) designed to address childhood overweight and obesity.

11 Sep 2009

Enlarged fat cells and waist-to-height ratios can cause diabetes in women

When it comes to assessing risk for type 2 diabetes, not only do waistlines matter to women, but so does the size of their fat cells. This new discovery by a team of Swedish researchers was just published online in the FASEB Journal (http://www.fasebj.org) and helps explain why some women of normal weight develop type 2 diabetes, despite not having any known risk factors.

11 Sep 2009

Phase II human clinical trial of Exsulin commences

Exsulin Corporation today announced the start of a phase II human clinical trial of Exsulin, a peptide drug product aimed at restoring insulin production in people with diabetes mellitus. The randomized, controlled 12-week trial in patients with established Type 1 diabetes (T1DM) will be co-led by Mayo Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, Canada.

10 Sep 2009

Three genes linked to Lou Gehrig's disease

Michigan Technological University researchers have linked three genes to the most common type of amyotrophic lateral sclerosis (ALS), generally known as Lou Gehrig's disease.

10 Sep 2009

VIVUS' Phase 3 studies find Qnexa effective in tackling obesity

VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.

9 Sep 2009

Nutrisystem D program helps overweight type 2 diabetic people lose weight

Results from a clinical study conducted at the Temple University School of Medicine and published today in the journal Postgraduate Medicine(1), show that a pre-packaged, portion controlled meal plan helped overweight individuals with type 2 diabetes lose significantly more weight and reduce their A1C test scores (a 90-day measure of blood sugar control) by almost a full point greater than those following a standard hospital-based diabetes support and education program, according to the findings.

9 Sep 2009

Regular usage of CGM devices help manage diabetes

The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors - six days per week or more - rather than the age of patients, and that benefits continue well past the time when people with type 1 diabetes begin using the devices - including experiencing fewer low blood sugar emergencies.

9 Sep 2009

Online destination resource for diabetics

Bayer Diabetes Care is continuing to simplify life for people with diabetes with the launch of simplewins.com, an online destination designed to inspire people with diabetes and help them meet the day-to-day challenges of living with and managing the disease.

9 Sep 2009

Proteostasis Therapeutics to use GeneGo's MetaCore integrated software

GeneGo, Inc., the leading systems biology tools company, announced today that Proteostasis Therapeutics has licensed its data mining and analysis platform, MetaCore. Proteostasis Therapeutics is the first company dedicated to the discovery of novel small molecule therapeutics based upon understanding the body's Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases.

8 Sep 2009

IRS1 gene could lead to better treatment of type 2 diabetes

A breakthrough by an international team of researchers in Canada, France, the UK and Denmark has uncovered a new gene that could lead to better treatment of type 2 diabetes, as well as a better understanding of how this widespread disease develops.

7 Sep 2009

Scientists identify new genetic variations that are associated with type 2 diabetes

Scientists have identified a genetic variation in people with type 2 diabetes that affects how the body's muscle cells respond to the hormone insulin, in a new study published today in Nature Genetics.

7 Sep 2009

Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials

Human Genome Sciences, Inc. today announced publication by the journal Arthritis Care & Research of an article describing the development and use of a novel evidence-based systemic lupus erythematosus (SLE) Responder Index selected as the primary endpoint of two pivotal Phase 3 clinical trials of BENLYSTA (belimumab) in serologically active patients with SLE.

4 Sep 2009

Takeda receives FDA response regarding NDA for fixed-dose combination of alogliptin and ACTOS

Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).

4 Sep 2009